Name
Abionic
What We Do
Abionic delivers sepsis detection through rapid diagnostics that enable clinicians to intervene up to 72 hours earlier than conventional methods. Our proprietary abioSCOPE® platform uses nanofluidic biosensor technology to provide lab-quality results from a single drop of blood in about 7 minutes, integrating smoothly into clinical workflows without complex training or maintenance.

At the heart of this innovation is our Pancreatic Stone Protein (PSP) test, a next-generation biomarker that rises before clinical symptoms appear. PSP supports early rule-in decisions even when standard indicators such as CRP and PCT are inconclusive. In ED, ICU, and burn settings, daily PSP monitoring helps guide decisions, distinguish infection from sterile inflammation, and initiate timely intervention before deterioration.

With CE marking and robust clinical validation in critical care environments, abioSCOPE® is trusted by healthcare professionals worldwide. Headquartered in Lausanne, Switzerland, with U.S. operations in Cambridge, Massachusetts, Abionic is committed to reducing diagnostic delays and improving outcomes for patients at risk of sepsis.
Categories
Diagnostic Products/Services, EMS/Pre-hospital, Infectious Disease, Medical Device and Equipment, Patient Monitoring, Pediatric Care, Point-of-Care Testing
Address
Route De La Corniche 5, Epalinges, Vaud, 1066
Epalinges,
Switzerland
LinkedIn